List of Excipients in Branded Drug BRIMONIDINE TARTRATE/TIMOLOL MALEATE OPHTHALMIC SOLUTION

« Back to Dashboard

Generic Drugs Containing BRIMONIDINE TARTRATE/TIMOLOL MALEATE OPHTHALMIC SOLUTION

Company	Ingredient	NDC	Excipient
Apotex Corp	brimonidine tartrate and timolol maleate	60505-0589	BENZALKONIUM CHLORIDE
Apotex Corp	brimonidine tartrate and timolol maleate	60505-0589	HYDROCHLORIC ACID
Apotex Corp	brimonidine tartrate and timolol maleate	60505-0589	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in BRIMONIDINE TARTRATE/TIMOLOL MALEATE OPHTHALMIC SOLUTION?

# Of NDCs	Excipient
4	BENZALKONIUM CHLORIDE
4	HYDROCHLORIC ACID
4	SODIUM HYDROXIDE

Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution: Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: September 24, 2026

Brimonidine tartrate/timolol maleate ophthalmic solution is a fixed-dose glaucoma combination with two established actives: brimonidine tartrate 0.2% and timolol maleate equivalent to timolol 0.5%. The reference product, Combigan, is an FDA-approved, twice-daily prescription ophthalmic solution marketed by AbbVie following its acquisition of Allergan. Its commercial opportunity is concentrated in generic substitution, preservative-free delivery, improved multidose packaging, international expansion, and differentiated tolerability.

The formulation uses benzalkonium chloride (BAK) at 0.005% as the preservative, phosphate buffering, sodium chloride, purified water, and pH adjustment agents. BAK reduction or elimination is the clearest formulation-led opportunity, but it increases manufacturing, packaging, microbiological, and regulatory complexity.

What is the FDA-approved formulation of brimonidine/timolol ophthalmic solution?

The reference formulation contains two active pharmaceutical ingredients in an aqueous sterile solution.

Component	Concentration or role
Brimonidine tartrate	0.2%
Timolol maleate	0.68%, equivalent to timolol 0.5%
Benzalkonium chloride	0.005% preservative
Sodium chloride	Tonicity adjustment
Sodium phosphate dibasic	Buffer
Sodium phosphate monobasic	Buffer
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Purified water	Vehicle

The labeled pH range is approximately 6.5 to 7.5. The product is supplied as a sterile multidose ophthalmic solution and is generally dosed as one drop in the affected eye or eyes twice daily.[1]

Why the active combination is commercially relevant

Brimonidine is an alpha-2 adrenergic agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. Timolol is a nonselective beta-adrenergic blocker that primarily reduces aqueous humor production. Combining the mechanisms can reduce intraocular pressure more effectively than either component alone in patients who require more than monotherapy.

The fixed combination reduces the number of bottles and administration steps. That creates a practical adherence advantage over separate brimonidine and timolol products, although the product retains the systemic and ocular safety limitations of both active ingredients.

What excipients protect the performance of the product?

The excipient system has four primary functions: preservation, pH control, tonicity adjustment, and chemical compatibility.

Benzalkonium chloride preservation

BAK at 0.005% enables multidose use by limiting microbial growth after repeated bottle access. It is effective at low concentration and is familiar to ophthalmic manufacturers and regulators.

Its commercial disadvantage is chronic ocular-surface tolerability. Long-term exposure may contribute to epithelial disruption, tear-film instability, conjunctival inflammation, and symptoms associated with ocular surface disease. Patients with glaucoma often use multiple preserved topical products, increasing cumulative BAK exposure.

A BAK-containing generic can be manufactured at lower cost and with a simpler container-closure system. A preservative-free product has greater differentiation potential but requires a more demanding microbiological control strategy.

Phosphate buffer

The phosphate system controls pH and supports chemical stability and patient comfort. The pH must balance several factors:

• Brimonidine and timolol stability
• Solubility of the active ingredients
• Ocular comfort
• Preservative performance
• Compatibility with the container
• Control of degradation products

Phosphate concentration should not be increased solely to improve buffering. Higher ionic strength can affect comfort, osmolality, preservative behavior, and manufacturing robustness.

Sodium chloride and osmolality

Sodium chloride adjusts tonicity toward a physiologically acceptable range. Excessive deviation from isotonicity can increase stinging and reflex tearing. Tonicity must be assessed after accounting for the ionization and salt forms of both active ingredients, the buffer system, and the preservative.

pH adjustment agents

Hydrochloric acid and sodium hydroxide provide final pH adjustment. The formulation should be evaluated for pH drift during accelerated and long-term storage, particularly after filling into the selected plastic container.

Purified water and sterile processing

The vehicle must meet pharmaceutical water requirements and support sterile manufacture. The product is an aqueous ophthalmic solution, so microbial control, bioburden management, filtration or sterilization strategy, and container-closure integrity are central development issues.

What formulation patents protect brimonidine/timolol ophthalmic solution?

The original combination product was protected by patents directed to the use and composition of brimonidine with timolol. U.S. Patent No. 6,780,882 is associated with the brimonidine/timolol combination and was a central patent in the historical exclusivity position for Combigan.[2]

The principal commercial patent risk has declined because the core combination patents have reached or approached their statutory expiration periods. Current manufacturers must still review:

• U.S. Orange Book listings for the reference NDA
• Continuation and divisional patents
• Formulation and container-closure claims
• Method-of-use claims
• Patent term adjustments or pediatric extensions
• Paragraph IV litigation and settlement records
• Jurisdiction-specific patent rights outside the United States

The exact patent position can differ by country. A generic that uses the same active concentrations but changes the preservative, buffer, packaging, or dosing presentation may avoid some claims while remaining exposed to other composition or method-of-use claims.

Are excipients themselves likely to create patent barriers?

Common excipients such as BAK, sodium chloride, phosphate salts, and purified water generally do not create meaningful standalone exclusivity. Patent exposure can arise from the combination of excipients, concentration ranges, pH, preservative-free delivery, container design, or a manufacturing process.

A company seeking a differentiated product should conduct freedom-to-operate review around:

1. Preservative-free multidose dispensers
2. Low-BAK formulations
3. Alternative buffer systems
4. Stabilized brimonidine/timolol solutions
5. Reduced-volume or controlled-drop delivery
6. Unit-dose packaging
7. Formulations directed to ocular-surface tolerability

When does brimonidine/timolol lose exclusivity?

The reference product received FDA approval in 2007. The core exclusivity period has expired, and the product is exposed to ANDA-based generic competition. The key commercial exclusivity barriers are now historical patent rights, regulatory approval timing, product quality, supply reliability, and formulary access rather than unexpired new chemical entity exclusivity.

Milestone	Commercial significance
2007 FDA approval of Combigan	Established the fixed-dose reference product
Core combination patent period	Delayed broad generic competition
Patent expiry period beginning in the early 2020s	Opened the market to ANDA applicants
Generic approvals	Increased price and formulary pressure
Post-exclusivity market	Shifted value toward cost, supply, tolerability, and packaging

FDA-approved generic products must demonstrate pharmaceutical equivalence and bioequivalence under the applicable ANDA framework. They do not need to repeat the full clinical development program conducted for the reference product, although they must satisfy FDA requirements for quality, sterility, stability, labeling, and manufacturing.[3]

What is the Orange Book status of brimonidine/timolol?

The reference product is listed in the FDA Orange Book under its NDA. Orange Book analysis should focus on listed patents, pediatric exclusivity, therapeutic equivalence codes for approved generics, and the status of each ANDA applicant.

A generic applicant may file:

• Paragraph I certification if no relevant patent is listed
• Paragraph II certification if the listed patent has expired
• Paragraph III certification accepting delayed approval until patent expiry
• Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed

Paragraph IV filings can trigger patent litigation under the Hatch-Waxman framework. Approval timing then depends on litigation, settlement, court decisions, and any applicable 30-month stay.

The commercial importance of a Paragraph IV strategy is lower once core patents have expired, but it can still matter for later-listed formulation or method-of-use patents. Applicants should avoid assuming that a change in excipients eliminates all patent exposure.

Which companies are challenging or competing with the reference product?

Competition comes from three product groups:

1. Fixed-dose brimonidine/timolol generics
2. Separate brimonidine and timolol products
3. Alternative fixed combinations such as dorzolamide/timolol and brimonidine/brinzolamide

Generic ophthalmic manufacturers that have participated in the broader glaucoma market include Apotex, Sandoz, Lupin, Teva, and other regional suppliers. Market participation varies by country, product presentation, and time.

The main competitive factors are:

Factor	Impact
Wholesale acquisition cost	Drives payer and pharmacy substitution
Product availability	Shortages can shift market share rapidly
Preservative profile	Relevant to chronic-use and ocular-surface patients
Bottle usability	Affects adherence and waste
Drop size	Influences dose consistency and economic value
Stability period	Supports inventory and distribution
Global registration	Determines addressable market
Manufacturing scale	Determines margin under generic pricing

What preservative-free opportunities exist?

Preservative-free development is the strongest formulation opportunity.

Unit-dose preservative-free solution

Single-use ampoules eliminate the need for antimicrobial preservation. The principal advantages are improved ocular-surface positioning and simpler patient messaging. The disadvantages are higher packaging cost, greater material consumption, more waste, and potential inconvenience for twice-daily chronic treatment.

The product must demonstrate:

• Sterility through the labeled shelf life
• Low extractables and leachables
• Adequate fill accuracy
• Container integrity
• Acceptable opening and administration behavior
• Chemical stability in the unit-dose material
• Transport robustness

Preservative-free multidose container

A multidose preservative-free system can offer better convenience and lower waste than unit-dose packaging. It requires a validated one-way valve, sterile air-management system, antimicrobial container design, or equivalent technology.

The principal risks are device complexity and human-use performance. A technically sophisticated dispenser can increase development cost, regulatory review time, manufacturing rejects, and supply-chain dependence.

Reduced-BAK formulation

A lower-BAK product may offer a middle position between conventional generic economics and fully preservative-free delivery. The commercial benefit depends on whether the lower concentration preserves microbiological robustness while producing a clinically meaningful tolerability advantage.

The claim strategy may also be more difficult. A lower preservative concentration can be commercially differentiated but may not produce strong patent protection without supporting stability, microbiological, or clinical data.

How strong is the commercial patent estate?

The core patent estate is weaker than it was during the branded exclusivity period because the principal combination protection has aged out. New commercial value is more likely to come from formulation, device, manufacturing, and market access than from the original active combination.

Estate area	Relative commercial strength
Brimonidine plus timolol combination	Low to moderate after core expiry
BAK-preserved aqueous solution	Low, due to established prior art
Preservative-free multidose delivery	Moderate to high if device claims are defensible
Unit-dose presentation	Low to moderate
Alternative buffers	Low unless tied to unexpected stability or tolerability
Container-closure technology	Moderate, depending on device novelty
Manufacturing process	Moderate if difficult to reproduce and claimable
Method-of-use claims	Variable and dependent on surviving listed patents

A robust strategy should not rely on a single composition patent. The strongest platform would combine a differentiated formulation, protected dispensing system, validated manufacturing process, and regulatory exclusivity where available.

What regulatory pathway applies to generic products?

A conventional generic product is generally submitted through an ANDA. The applicant must match the reference product in active ingredients, strength, dosage form, route of administration, and other applicable requirements. The formulation may contain permissible differences in inactive ingredients if the product remains pharmaceutically equivalent and safe.

A reformulated preservative-free product may still qualify for an ANDA if it meets the relevant sameness requirements. Significant differences in formulation, delivery system, or clinical use can push development toward a 505(b)(2) application.

FDA review will focus on:

• Assay and impurity control
• Sterility assurance
• Preservative effectiveness where applicable
• Particulate matter
• pH and osmolality
• Drop size and delivered volume
• Container-closure integrity
• Extractables and leachables
• In-use stability
• Stability after opening
• Comparative performance against the reference product

What generic launch risks exist?

A generic launch can occur rapidly after patent barriers fall, but ophthalmic products have higher operational risk than many oral solids.

The principal risks are:

• Sterility failures
• Bottle or nozzle clogging
• Variable drop size
• Preservative loss through adsorption
• pH drift
• Brimonidine or timolol degradation
• Container interaction
• Manufacturing-site inspection findings
• API supply disruption
• Price erosion after multiple entrants
• Substitution losses to established generic suppliers

The market is particularly sensitive to reliable supply. A manufacturer with a slightly higher price but consistent availability can outperform a lower-cost supplier during shortages.

How does brimonidine/timolol compare with competing glaucoma combinations?

Product	Active ingredients	Typical commercial position
Brimonidine/timolol	Alpha-2 agonist plus beta blocker	Fixed combination for patients requiring dual therapy
Dorzolamide/timolol	Carbonic anhydrase inhibitor plus beta blocker	Established alternative dual therapy
Brimonidine/brinzolamide	Alpha-2 agonist plus carbonic anhydrase inhibitor	Beta-blocker-free combination
Separate brimonidine plus timolol	Two products	Flexible dosing but higher administration burden

Brimonidine/timolol has a clear convenience benefit over separate therapy. Its main disadvantages are beta-blocker contraindications and the ocular-surface burden associated with chronic preserved use.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve delivery technology than the active ingredients. The active combination is well established, and a conventional BAK-preserved generic has limited differentiation.

Potential transaction structures include:

• Regional licensing of an approved generic
• In-licensing of a preservative-free ophthalmic platform
• Contract development and manufacturing agreements
• Co-development of a multidose sterile dispenser
• Authorized generic arrangements
• Portfolio bundling with other glaucoma products
• Supply agreements for hospital and government tenders

A partner with an established ophthalmic manufacturing site can reduce validation and inspection risk. A device company may provide stronger differentiation than a conventional formulation partner.

What is the revenue exposure and commercial opportunity?

The reference product’s revenue exposure has shifted from branded exclusivity to chronic-use volume. Ophthalmic glaucoma therapy is recurring, and fixed combinations can retain demand after generic entry because many patients remain on stable therapy.

The opportunity is segmented:

Segment	Opportunity
Commodity generic	Volume-driven, low margin
Authorized generic	Moderate margin with reference-product credibility
Preservative-free unit dose	Premium pricing and differentiated tolerability
Preservative-free multidose	Highest strategic value if device performs reliably
Emerging markets	Lower price but broader access potential
Hospital tenders	High volume and severe price competition
Private-label supply	Distribution access and manufacturing utilization

Revenue forecasting should model generic entrant count, substitution rate, tender pricing, product availability, and the premium that payers or prescribers will accept for preservative-free delivery.

Key Takeaways

• Brimonidine tartrate/timolol maleate ophthalmic solution combines brimonidine 0.2% and timolol 0.5% in a sterile aqueous formulation.
• The reference product uses BAK 0.005%, phosphate buffer, sodium chloride, purified water, and pH adjustment agents.
• Core combination exclusivity has largely expired, making conventional generic competition the main market structure.
• The strongest commercial opportunity is a preservative-free or reduced-BAK product with reliable multidose delivery.
• Unit-dose products offer a simpler preservative-free strategy but carry higher packaging cost and waste.
• Device patents, container-closure claims, manufacturing controls, and regulatory execution are more important than new active-ingredient patents.
• This product is regulated as a small-molecule ophthalmic drug, not a biologic; biosimilar risk does not apply.
• Generic launch economics depend on sterile manufacturing, drop-size consistency, supply reliability, and payer access.
• A differentiated licensing strategy should center on ophthalmic delivery technology, not the already established active combination.

FAQs

Is brimonidine/timolol ophthalmic solution a biologic or biosimilar product?

No. It is a small-molecule fixed-dose ophthalmic drug. Competing products are filed primarily through the ANDA pathway as generics rather than through a biosimilar application.

Can benzalkonium chloride be removed from the formulation?

Yes, but removal requires a redesigned preservative and packaging strategy. The product may use single-dose containers or a validated preservative-free multidose dispenser.

Does a lower BAK concentration automatically create a patentable product?

No. Patentability depends on novelty, non-obviousness, claim scope, and supporting technical evidence. A lower preservative concentration alone may not provide durable exclusivity.

Which manufacturing capability is most important for this product?

Sterile ophthalmic manufacturing with strong container-closure, microbiological, and in-use stability controls is the critical capability. Device assembly and drop-delivery testing are also important for differentiated presentations.

Can a company sell brimonidine/timolol as an over-the-counter product?

The product is prescription-only in the United States. A commercial launch would require an approved prescription pathway unless FDA separately authorizes a nonprescription switch.

References

1. U.S. Food and Drug Administration. (2024). Combigan (brimonidine tartrate and timolol maleate ophthalmic solution) prescribing information.
2. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,780,882: Combination of brimonidine and timolol for treatment of glaucoma.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.